MRSN - Mersana Therapeutics, Inc.
29.08
0.040 0.138%
Share volume: 712,460
Last Updated: 01-05-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$29.04
0.04
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-09-2024 | 08-13-2024 | 11-13-2024 | 03-03-2025 | 05-15-2025 | 08-13-2025 | 11-14-2025 | |
| Total revenue | 9.245 M | 2.293 M | 12.598 M | 16.361 M | 2.754 M | 3.056 M | 11.009 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 9.245 M | 2.293 M | 12.598 M | 16.361 M | 2.754 M | 3.056 M | 11.009 M | |
| -75.20% | 449.41% | 29.87% | -83.17% | 10.97% | 260.24% | |||
| Operating expenses | 30.246 M | 27.748 M | 24.667 M | 31.172 M | 27.266 M | 23.633 M | 18.485 M | |
| Selling general and admin | 11.560 M | 10.503 M | 9.864 M | 8.886 M | 8.925 M | 7.415 M | 6.303 M | |
| Research and development | 18.686 M | 17.245 M | 14.803 M | 22.286 M | 18.341 M | 16.218 M | 12.182 M | |
| Total expenses | 30.246 M | 27.748 M | 24.667 M | 31.172 M | 27.266 M | 27.573 M | 18.676 M | |
| -8.26% | -11.10% | 26.37% | -12.53% | 1.13% | -32.27% | |||
| Operating income | -21.001 M | -25.455 M | -12.069 M | -14.811 M | -24.512 M | -24.517 M | -7.667 M | |
| Ebit | -21.001 M | -25.455 M | -12.069 M | -14.811 M | -24.512 M | -24.517 M | -7.667 M | |
| Pretax income | -19.306 M | -24.268 M | -11.083 M | -14.117 M | -24.123 M | -24.296 M | -7.545 M | |
| 25.70% | -54.33% | 27.38% | 70.88% | 0.72% | -68.95% | |||
| Income tax | 0.000 | 0.000 | 418.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -19.306 M | -24.268 M | -11.501 M | -14.117 M | -24.123 M | -24.296 M | -7.545 M | |
| -25.70% | 52.61% | -22.75% | -70.88% | -0.72% | 68.95% |